<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NADOLOL AND BENDROFLUMETHIAZIDE- nadolol and bendroflumethiazide tablet </strong><br>Global Pharmaceuticals, Division of Impax Laboratories, Inc.<br></p></div>
<h1>NADOLOL AND<br> BENDROFLUMETHIAZIDE<br> TABLETS, USP,<br> 40 mg/5 mg AND 80 mg/5 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Nadolol and bendroflumethiazide tablets for oral administration combine two antihypertensive agents: nadolol, a nonselective beta-adrenergic blocking agent, and bendroflumethiazide, a thiazide diuretic-antihypertensive.</p>
<p>Each tablet contains 40 mg or 80 mg nadolol combined with 5 mg bendroflumethiazide. Inactive ingredients: croscarmellose sodium, hypromellose (type 2910), lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, pregelatinized starch and talc.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Nadolol</h2>
<p class="First">Nadolol is a white crystalline powder. It is freely soluble in ethanol, soluble in hydrochloric acid, slightly soluble in water and in chloroform, and very slightly soluble in sodium hydroxide.</p>
<p>Nadolol is designated chemically as 1-(<span class="Italics">tert</span>-butylamino)-3-{(5,6,7,8-tetrahydro-<span class="Italics">cis</span>-6,7-dihydroxy-1-naphthyl)oxy}-2-propanol. Structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f&amp;name=nadolol-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Bendroflumethiazide</h2>
<p class="First">Bendroflumethiazide is a white crystalline powder. It is soluble in alcohol and in sodium hydroxide, and insoluble in hydrochloric acid, water, and chloroform.</p>
<p>Bendroflumethiazide is designated chemically as 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f&amp;name=nadolol-02.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Nadolol</h2>
<p class="First">Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and (4) reduction of reflex orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Nadolol specifically competes with beta-adrenergic receptor agonists for available beta receptor sites; it inhibits both the beta<span class="Sub">1 </span>receptors located chiefly in cardiac muscle and the beta<span class="Sub">2 </span>receptors located chiefly in the bronchial and vascular musculature, inhibiting the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation proportionately. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. Animal and human studies show that nadolol slows the sinus rate and depresses AV conduction. In dogs, only minimal amounts of nadolol were detected in the brain relative to amounts in blood and other organs and tissues. Nadolol has low lipophilicity as determined by octanol/water partition coefficient, a characteristic of certain beta-blocking agents that has been correlated with the limited extent to which these agents cross the blood-brain barrier, their low concentration in the brain, and low incidence of CNS-related side effects.</p>
<p>In controlled clinical studies, nadolol at doses of 40 to 320 mg/day has been shown to decrease both standing and supine blood pressure, the effect persisting for approximately 24 hours after dosing.</p>
<p>The mechanism of the antihypertensive effects of beta-adrenergic receptor blocking agents has not been established; however, factors that may be involved include (1) competitive antagonism of catecholamines at peripheral (non-CNS) adrenergic neuron sites (especially cardiac) leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, (2) a central effect leading to reduced tonic-sympathetic nerve outflow to the periphery, and (3) suppression of renin secretion by blockade of the beta-adrenergic receptors responsible for renin release from the kidneys.</p>
<p>While <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial pressure are reduced by nadolol therapy, renal hemodynamics are stable, with preservation of renal blood flow and glomerular filtration rate.</p>
<p>By blocking catecholamine-induced increases in heart rate, velocity and extent of myocardial contraction, and blood pressure, nadolol generally reduces the oxygen requirements of the heart at any given level of effort, making it useful for many patients in the long-term management of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. On the other hand, nadolol can increase oxygen requirements by increasing left ventricular fiber length and end diastolic pressure, particularly in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p>Although beta-adrenergic receptor blockade is useful in treatment of angina and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta<span class="Sub">2</span>-adrenergic blockade may worsen <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta<span class="Sub">2</span>-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and may also interfere with exogenous bronchodilators in such patients.</p>
<p>Absorption of nadolol after oral dosing is variable, averaging about 30 percent. Peak serum concentrations of nadolol usually occur in three to four hours after oral administration and the presence of food in the gastrointestinal tract does not affect the rate or extent of nadolol absorption. Approximately 30 percent of the nadolol present in serum is reversibly bound to plasma protein.</p>
<p>Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys.</p>
<p>The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting once-daily dosage. Because nadolol is excreted predominantly in the urine, its half-life increases in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <span class="Bold"><a href="#gen">PRECAUTIONS, General</a></span>, and <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>). Steady state serum concentrations of nadolol are attained in six to nine days with once-daily dosage in persons with normal renal function. Because of variable absorption and different individual responsiveness, the proper dosage must be determined by titration.</p>
<p>Exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Abrupt withdrawal of these agents in patients without <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> has resulted in transient symptoms, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Bendroflumethiazide</h2>
<p class="First">The mechanism of action of bendroflumethiazide results in an interference with the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic potency.</p>
<p>Thiazides increase excretion of sodium and chloride in approximately equivalent amounts. Natriuresis causes a secondary loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not affect normal blood pressure.</p>
<p>Onset of action of thiazides occurs in two hours and the peak effect at about four hours. Duration of action persists for approximately six to 12 hours. Thiazides are eliminated rapidly by the kidney.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Nadolol and bendroflumethiazide tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets.</p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p>Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contrain"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Nadolol</h2>
<p class="First">Nadolol is contraindicated in bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> and greater than first degree conduction block, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, and overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Bendroflumethiazide</h2>
<p class="First">Bendroflumethiazide is contraindicated in <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. It is also contraindicated in patients who have previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to bendroflumethiazide or other sulfonamide-derived drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="warn_nad"></a><a name="section-6.1"></a><p></p>
<h2>Nadolol</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h3>
<p class="First">Sympathetic stimulation may be a vital component supporting circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, if necessary, they can be used with caution in patients with a history of failure who are well compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.</p>
<p>IN PATIENTS WITHOUT A HISTORY OF <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, continued use of beta-blockers can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Therefore, at the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the patient should be digitalized and/ or treated with diuretics, and the response observed closely, or nadolol should be discontinued (gradually, if possible).</p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Emphasis">Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt Withdrawal</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt </span>discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>)</h3>
<p class="First">PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Nadolol should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta<span class="Sub">2 </span>receptors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="major"></a><a name="section-6.1.3"></a><p></p>
<h3>Major Surgery</h3>
<p class="First">Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h3>
<p class="First">Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and blood pressure changes) of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; therefore, it may be necessary to adjust the dose of antidiabetic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h3>
<p class="First">Beta-adrenergic blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="warn_ben"></a><a name="section-6.2"></a><p></p>
<h2>Bendroflumethiazide</h2>
<p class="First">Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Sensitivity reactions may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>The possibility of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.</p>
<p>Lithium generally should not be given with diuretics; diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such concomitant therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRE"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="gen"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Nadolol</h3>
<p class="First">Nadolol should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="gen_ben"></a><a name="section-7.1.2"></a><p></p>
<h3>Bendroflumethiazide</h3>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, namely: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may include: dryness of the mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or when severe cirrhosis is present.</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>). Concurrent administration of a potassium-sparing diuretic or potassium supplements may be indicated in these patients.</p>
<p>Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">Latent diabetes</span> mellitus may become manifest during thiazide administration.</p>
<p>The antihypertensive effect of thiazide diuretics may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen (BUN), a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.</p>
<p>Thiazides may decrease serum PBI levels without signs of thyroid disturbance.</p>
<p>Calcium excretion is decreased by thiazides. Pathological changes in the parathyroid gland with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. The common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> have not been seen. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of therapy without the physician's advice. Although <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure.</p>
<p>The patient should also be advised of a proper course in the event of an inadvertently missed dose.</p>
<p>The patient should be informed of symptoms that would suggest potential adverse effects and told to report them promptly.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum electrolyte levels should be regularly monitored (see <span class="Bold"><a href="#warn_ben">WARNINGS, Bendroflumethiazide</a></span>, also <span class="Bold"><a href="#gen_ben">PRECAUTIONS, General, Bendroflumethiazide</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.1"></a><p></p>
<h3>Nadolol</h3>
<p class="First">When administered concurrently the following drugs may interact with beta-adrenergic receptor blocking agents:</p>
<p><span class="Italics">Anesthetics, general</span>-exaggeration of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> induced by general anesthetics (see <span class="Bold"><a href="#major">WARNINGS, Nadolol, Major Surgery</a></span>).</p>
<p><span class="Italics">Antidiabetic drugs (oral agents and insulin)</span>-<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; adjust dosage of antidiabetic drug accordingly (see <span class="Bold"><a href="#<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>">WARNINGS, Nadolol, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></span>).</p>
<p><span class="Italics">Catecholamine-depleting drugs (e.g., reserpine)</span>- additive effect; monitor closely for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (e.g., <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>).</p>
<p><span class="Italics">Response to Treatment for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></span>-While taking beta-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4.2"></a><p></p>
<h3>Bendroflumethiazide</h3>
<p class="First">When administered concurrently the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics</span>-potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Amphotericin B, corticosteroids, or corticotropin (ACTH)</span>-may intensify <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Monitor potassium levels; use potassium replacements if necessary.</p>
<p><span class="Italics">Anticoagulants (oral)</span>-dosage adjustments of anticoagulant medication may be necessary since bendroflumethiazide may decrease their effects.</p>
<p><span class="Italics">Antigout medications</span>-dosage adjustments of antigout medication may be necessary since bendroflumethiazide may raise the level of blood uric acid.</p>
<p><span class="Italics">Other antihypertensive medications (e.g., ganglionic or peripheral adrenergic blocking agents</span>)-dosage adjustments may be necessary since bendroflumethiazide may potentiate their effects.</p>
<p><span class="Italics">Antidiabetic drugs (oral agents and insulin)</span>-since thiazides may elevate blood glucose levels, dosage adjustments of antidiabetic agents may be necessary.</p>
<p><span class="Italics">Calcium salts</span>-increased serum calcium levels due to decreased excretion may occur. If calcium must be prescribed monitor serum calcium levels and adjust calcium dosage accordingly.</p>
<p><span class="Italics">Cardiac glycosides</span>-enhanced possibility of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> associated with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Monitor potassium levels; use potassium replacement if necessary.</p>
<p><span class="Italics">Cholestyramine resin and colestipol HCl</span>-may delay or decrease absorption of bendroflumethiazide. Sulfonamide diuretics should be taken at least one hour before or four to six hours after these medications.</p>
<p><span class="Italics">Diazoxide</span>-enhanced hyperglycemic, hyperuricemic, and antihypertensive effects. Be cognizant of possible interaction; monitor blood glucose and serum uric acid levels.</p>
<p><span class="Italics">Lithium salts</span>-may enhance <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> due to reduced renal clearance. Avoid concurrent use; if lithium must be prescribed monitor serum lithium levels and adjust lithium dosage accordingly. (See <span class="Bold"><a href="#warnings">WARNINGS</a></span>)</p>
<p><span class="Italics">MAO inhibitors</span>-dosage adjustments of one or both agents may be necessary since hypotensive effects are enhanced.</p>
<p><span class="Italics">Nondepolarizing muscle relaxants, preanesthetics and anesthetics used in surgery (e.g., tubocurarine chloride and gallamine triethiodide)</span>-effects of these agents may be potentiated; dosage adjustments may be required. Monitor and correct any fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span> prior to surgery if feasible.</p>
<p><span class="Italics">Nonsteroidal anti-inflammatory agents</span>-in some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effect of loop, potassium-sparing or thiazide diuretics. Therefore, when bendroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
<p><span class="Italics">Methenamine</span>-possible decreased effectiveness due to alkalinization of the urine.</p>
<p><span class="Italics">Pressor amines (e.g., norepinephrine)</span>-decreased arterial responsiveness, but not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Use caution in patients taking both medications who undergo surgery. Administer preanesthetic and anesthetic agents in reduced dosage, and if possible, discontinue bendroflumethiazide one week prior to surgery.</p>
<p><span class="Italics">Probenecid or sulfinpyrazone</span>-increased dosage of these agents may be necessary since bendroflumethiazide may have hyperuricemic effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Bendroflumethiazide may produce false-negative results with the phentolamine and tyramine tests; may interfere with the phenosulfonphthalein test due to decreased excretion; and it may cause diagnostic interference of serum electrolyte levels, blood and urine glucose levels, and a decrease in serum PBI levels without signs of thyroid disturbance.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1"></a><p></p>
<h3>Nadolol</h3>
<p class="First">In chronic oral toxicologic studies (one to two years) in mice, rats, and dogs, nadolol did not produce any significant toxic effects. In two-year oral carcinogenicity studies in rats and mice, nadolol did not produce any neoplastic, preneoplastic, or nonneoplastic pathologic lesions. In fertility and general reproductive performance studies in rats, nadolol caused no adverse effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.2"></a><p></p>
<h3>Bendroflumethiazide</h3>
<p class="First">Studies have not been performed to evaluate carcinogenic potential, mutagenesis, or whether this drug adversely affects fertility in males or females.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.7.1"></a><p></p>
<h3>Pregnancy-Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1"></a><p></p>
<h4>Nadolol</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.1.1"></a><p></p>
<h5>Category C</h5>
<p class="First">In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits, but not in rats or hamsters, at doses 5 to 10 times greater (on a mg/kg basis) than the maximum indicated human dose. No teratogenic potential was observed in any of these species.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Nadolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates whose mothers are receiving nadolol at parturition have exhibited <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and associated symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.2"></a><p></p>
<h4>Bendroflumethiazide</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1.2.1"></a><p></p>
<h5>Category C</h5>
<p class="First">Animal reproduction studies have not been conducted with bendroflumethiazide. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Bendroflumethiazide should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.7.2"></a><p></p>
<h3>Pregnancy-Nonteratogenic Effects</h3>
<p class="First">Thiazides cross the placental barrier and appear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Both nadolol and bendroflumethiazide are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from both drugs, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the importance of nadolol and bendroflumethiazide tablets to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of nadolol and bendroflumethiazide tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reaction to this drug may be greater in patients with impaired function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Nadolol</h2>
<p class="First">Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.</p>
<p><span class="Italics">Cardiovascular</span>-<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> were seen in about 2 of 100 patients. Symptoms of peripheral <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span>, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> have been reported; intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> is a known effect of beta-blockers (see also <span class="Bold"><a href="#contrain">CONTRAINDICATIONS</a>, <a href="#warnings">WARNINGS</a>,</span> and <span class="Bold"><a href="#PRE">PRECAUTIONS</a></span>).</p>
<p><span class="Italics">Central Nervous System</span>-<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> has been reported in approximately 2 of 100 patients; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, sedation, and change in behavior have each been reported in approximately 6 of 1000 patients.</p>
<p><span class="Italics">Respiratory</span>-<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> has been reported in approximately 1 of 1000 patients (see <span class="Bold"><a href="#contrain">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
<p><span class="Italics">Gastrointestinal</span>-<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> have been reported in 1 to 5 of 1000 patients.</p>
<p><span class="Italics">Miscellaneous</span>-Each of the following has been reported in 1 to 5 of 1000 patients: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, eyes, or skin; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> or decreased libido; <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>; <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>; <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> has been reported infrequently.</p>
<p>The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.</p>
<p><span class="Italics">Central Nervous System</span>-Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> with slightly clouded sensorium, and decreased performance on neuropsychometrics.</p>
<p><span class="Italics">Gastrointestinal</span>-Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>; <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; elevated liver enzymes.</p>
<p><span class="Italics">Hematologic</span>-<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; thrombocytopenic or nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Italics">Allergic</span>-<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>; <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>; <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
<p><span class="Italics">Miscellaneous</span>-<span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">Pemphigoid</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; hypertensive reaction in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>; <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>; Peyronie's disease.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol has not been reported with nadolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Bendroflumethiazide</h2>
<p class="First"><span class="Italics">Gastrointestinal</span>-<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, cramping and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> are not uncommon; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span> occasionally occur; and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> has been reported.</p>
<p><span class="Italics">Central Nervous System</span>-<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span> occasionally occur.</p>
<p><span class="Italics">Hematologic</span>-<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported.</p>
<p><span class="Italics">Dermatologic-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span>-<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> occasionally occur; <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have been reported.</p>
<p><span class="Italics">Cardiovascular</span>-<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may occur and may be potentiated by coadministration with certain other drugs (e.g., alcohol, barbiturates, narcotics, other antihypertensive medications, etc.; see <span class="Bold"><a href="#DI">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p><span class="Italics">Other</span>-<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> is not uncommon; <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in diabetic patients, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, allergic <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, and transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> occasionally occur.</p>
<p>Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of overdosage, nadolol may cause excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.</p>
<p>In addition to the expected <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, overdosage of bendroflumethiazide may produce varying degrees of <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> which may progress to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> with minimal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration and cardiovascular function and without significant serum electrolyte changes or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. The mechanism of thiazide-induced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> is unknown. <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">Gastrointestinal irritation</span> may occur. Transitory increase in BUN has been reported, and serum electrolyte changes may occur, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Nadolol can be removed from the general circulation by hemodialysis. In determining the duration of corrective therapy, note must be taken of the long duration of the effect of nadolol. In addition to gastric lavage, the following measures should be employed, as appropriate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.1"></a><p></p>
<h3>Excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></h3>
<p class="First">Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h3>
<p class="First">Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h3>
<p class="First">Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h3>
<p class="First">Administer a beta<span class="Sub">2</span>-stimulating agent and/or a theophylline derivative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span></h3>
<p class="First">Supportive therapy as warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.6"></a><p></p>
<h3>Gastrointestinal Effects</h3>
<p class="First">Symptomatic treatment as needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.7"></a><p></p>
<h3>BUN and/or Serum Electrolyte Abnormalities</h3>
<p class="First">Institute supportive measures as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED (SEE <span class="Bold"><a href="#indications">INDICATIONS</a></span>). NADOLOL AND BENDROFLUMETHIAZIDE TABLETS MAY BE ADMINISTERED WITHOUT REGARD TO MEALS.</p>
<p>Bendroflumethiazide is usually given at a dose of 5 mg daily. The usual initial dose of nadolol is 40 mg once daily whether used alone or in combination with a diuretic. Bendroflumethiazide in nadolol and bendroflumethiazide tablets is 30 percent more bioavailable than that of 5 mg bendroflumethiazide tablets. Conversion from 5 mg bendroflumethiazide tablets to nadolol and bendroflumethiazide tablets represents a 30 percent increase in dose of bendroflumethiazide.</p>
<p>The initial dose of nadolol and bendroflumethiazide tablets may therefore be the 40 mg/5 mg tablet once daily. When the antihypertensive response is not satisfactory, the dose may be increased by administering the 80 mg/5 mg tablet once daily.</p>
<p>When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First">Absorbed nadolol is excreted principally by the kidneys and, although nonrenal elimination does occur, dosage adjustments are necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The following dose intervals are recommended:</p>
<table width="50%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Creatinine Clearance<br>(mL/min/1.73 m<span class="Sup">2</span>)</th>
<th class="Lrule Rrule" align="center">Dosage Interval<br>(hours)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">&gt;50</td>
<td class="Lrule Rrule" align="center">24</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">31 to 50</td>
<td class="Lrule Rrule" align="center">24 to 36</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">10 to 30</td>
<td class="Lrule Rrule" align="center">24 to 48</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">&lt;10</td>
<td class="Lrule Rrule" align="center">40 to 60</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nadolol and bendroflumethiazide tablets, 40 mg/5 mg, contain 40 mg nadolol combined with 5 mg bendroflumethiazide, and are white to off-white, round, bi-convex tablets debossed with "G" bisect "531" on one side and plain on the other.</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="left">Bottles of 100</td>
<td align="left">NDC 0115-5311-01</td>
</tr>
<tr>
<td align="left">Bottles of 500</td>
<td align="left">NDC 0115-5311-02</td>
</tr>
</tbody>
</table>
<p>Nadolol and bendroflumethiazide tablets, 80 mg/5 mg, contain 80 mg nadolol combined with 5 mg bendroflumethiazide, and are white to off-white, round, bi-convex tablets debossed with "G" bisect "532" on one side and plain on the other.</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="left">Bottles of 100</td>
<td align="left">NDC 0115-5322-01</td>
</tr>
<tr>
<td align="left">Bottles of 500</td>
<td align="left">NDC 0115-5322-02</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tightly-closed, light-resistant container as defined in the USP, with a child-resistant closure, as required.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Mfg. by:<br>IMPAX Laboratories, Inc.<br>Hayward, CA 94544 USA</p>
<p>Dist. by:<br>Global Pharmaceuticals<br>Division of IMPAX Laboratories, Inc.<br>Philadelphia, PA 19124 USA</p>
<p>522-02<br>Rev. 10/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 40 mg/5 mg Bottle Label</h1>
<p class="First"><span class="Bold">GLOBAL</span><span class="Sup">®</span></p>
<p>NDC 0115-5311-02</p>
<p><span class="Bold">Nadolol and<br>Bendroflumethiazide<br>Tablets, USP</span></p>
<p><span class="Bold">40 mg/5 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">500 TABLETS</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg/5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f&amp;name=nadolol-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 80 mg/5 mg Bottle Label</h1>
<p class="First"><span class="Bold">GLOBAL</span><span class="Sup">®</span></p>
<p>NDC 0115-5322-02</p>
<p><span class="Bold">Nadolol and<br>Bendroflumethiazide<br>Tablets, USP</span></p>
<p><span class="Bold">80 mg/5 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">500 TABLETS</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 80 mg/5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f&amp;name=nadolol-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NADOLOL AND BENDROFLUMETHIAZIDE 		
					</strong><br><span class="contentTableReg">nadolol and bendroflumethiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0115-5311</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NADOLOL</strong> (NADOLOL) </td>
<td class="formItem">NADOLOL</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENDROFLUMETHIAZIDE</strong> (BENDROFLUMETHIAZIDE) </td>
<td class="formItem">BENDROFLUMETHIAZIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, bi-convex tablets) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;531</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0115-5311-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0115-5311-02</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077833</td>
<td class="formItem">03/30/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NADOLOL AND BENDROFLUMETHIAZIDE 		
					</strong><br><span class="contentTableReg">nadolol and bendroflumethiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0115-5322</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NADOLOL</strong> (NADOLOL) </td>
<td class="formItem">NADOLOL</td>
<td class="formItem">80 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENDROFLUMETHIAZIDE</strong> (BENDROFLUMETHIAZIDE) </td>
<td class="formItem">BENDROFLUMETHIAZIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, bi-convex tablets) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;532</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0115-5322-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0115-5322-02</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077833</td>
<td class="formItem">03/30/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Global Pharmaceuticals, Division of Impax Laboratories, Inc.
							(116732830)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Global Pharmaceuticals, Division of Impax Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">116732830</td>
<td class="formItem">REPACK(0115-5311, 0115-5322)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6e424468-1209-4462-93fe-bccdd45d2ff2</div>
<div>Set id: d2d226ea-1624-47ee-82bf-e9660b75029f</div>
<div>Version: 4</div>
<div>Effective Time: 20131023</div>
</div>
</div> <div class="DistributorName">Global Pharmaceuticals, Division of Impax Laboratories, Inc.</div></p>
</body></html>
